|Systematic (IUPAC) name|
|5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline- 7-carboxylic acid|
|(what is this?)|
Oxolinic acid is a quinolone antibiotic developed in Japan in the 1970s. Dosages 12–20 mg/kg orally administered for five to ten days. The antibiotic works by inhibiting the enzyme DNA gyrase. It also acts as a dopamine reuptake inhibitor and has stimulant effects in mice.
- JP Patent 49138244
- Gleckman R, Alvarez S, Joubert DW, Matthews SJ (August 1979). "Drug therapy reviews: oxolinic acid". American Journal of Hospital Pharmacy 36 (8): 1077–9. PMID 384788.
- Garcia de Mateos-Verchere J, Vaugeois JM, Naudin B, Costentin J (December 1998). "Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 8 (4): 255–9. doi:10.1016/S0924-977X(97)00083-7. PMID 9928913.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|